The Clinical Evaluation Consultation Procedure (CECP), established under Article 54 of Regulation (EU) 2017/745 (MDR), represents a unique mechanism within the European medical device regulatory framework.
Through the involvement of independent Expert Panels, the procedure aims to provide an additional level of scrutiny for certain high-risk devices before they are placed on the
market. The underlying objective is to strengthen patient safety, improve confidence in regulatory decision-making, and promote consistency in the evaluation of clinical evidence across Europe.
Several years into implementation, Notified Bodies (NBs) have accumulated substantial experience with the CECP process. That experience demonstrates clear strengths. Expert Panels have generally respected statutory timelines, engagement between Notified Bodies and Panels has improved significantly, and the procedure has contributed to increased attention on the quality and robustness of clinical evidence.
At the same time, challenges remain. The current process can create significant administrative burden, uncertainty regarding evidentiary expectations, prolonged certification timelines, and concerns regarding the practical impact of public negative opinions. Experience has also highlighted opportunities to improve predictability, transparency, and regulatory effectiveness while maintaining a high level of patient protection.
This paper presents a balanced assessment of the CECP and proposes targeted improvements for consideration during future MDR revision discussions.

